SG11201909895UA - Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles - Google Patents
Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 allelesInfo
- Publication number
- SG11201909895UA SG11201909895UA SG11201909895UA SG11201909895UA SG 11201909895U A SG11201909895U A SG 11201909895UA SG 11201909895U A SG11201909895U A SG 11201909895UA SG 11201909895U A SG11201909895U A SG 11201909895UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- alzheimer
- disease
- treatment
- receptor antagonist
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title abstract 3
- 108700028369 Alleles Proteins 0.000 title abstract 3
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 239000003751 serotonin 6 antagonist Substances 0.000 title abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 29 November 2018 (29.11.2018) WIPO I PCT ~ill IIIIIIIIII1101OlDIIIIIIIHo DVIIIIIIIIIIIIIIIIMDIIIIII ° iflo oimIE (10) International Publication Number WO 2018/215478 Al (51) International Patent Classification: A61K 31/4045 (2006.01) A61K 31/27 (2006.01) A61K 31/445 (2006.01) A61K 31/55 (2006.01) A61K 31/496 (2006.01) A61K 45/06 (2006.01) A61K 31/505 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/EP2018/063402 (22) International Filing Date: 22 May 2018 (22.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA201700313 24 May 2017 (24.05.2017) DK PA201700538 29 September 2017 (29.09.2017) DK (71) Applicant: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, 2500 Valby (DK). (72) Inventor: WINDFELD, Kristian; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) 00 N 11 ! (54) Title: COMBINATION OF A 5-HT6 RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR FOR 00 USE IN THE TREATMENT OF ALZHEIMER'S DISEASE IN A PATIENT SUBPOPULATION CARRYING APOE4 ALLELES O 1-1 (57) : The present invention relates to 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease, wherein the Alzheimer's disease patient carries one or two ApoE4 alleles, comprising administering an effective dose of a 5-HT 6 receptor antagonist C to improve or augment the effect of an acetylcholinesterase inhibitor.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201700313 | 2017-05-24 | ||
| DKPA201700538 | 2017-09-29 | ||
| PCT/EP2018/063402 WO2018215478A1 (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909895UA true SG11201909895UA (en) | 2019-11-28 |
Family
ID=62235961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909895U SG11201909895UA (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11464759B2 (en) |
| EP (1) | EP3630098B1 (en) |
| JP (1) | JP7167065B2 (en) |
| KR (1) | KR102676011B1 (en) |
| CN (1) | CN111032038A (en) |
| AU (1) | AU2018272883B2 (en) |
| BR (1) | BR112019001145A2 (en) |
| CA (1) | CA3063968A1 (en) |
| CY (1) | CY1124282T1 (en) |
| DK (1) | DK3630098T3 (en) |
| ES (1) | ES2869128T3 (en) |
| HR (1) | HRP20210634T1 (en) |
| HU (1) | HUE053636T2 (en) |
| LT (1) | LT3630098T (en) |
| MX (1) | MX2019013912A (en) |
| PL (1) | PL3630098T3 (en) |
| PT (1) | PT3630098T (en) |
| RS (1) | RS61704B1 (en) |
| SG (1) | SG11201909895UA (en) |
| SI (1) | SI3630098T1 (en) |
| WO (1) | WO2018215478A1 (en) |
| ZA (1) | ZA201907525B (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2566056T3 (en) | 2001-03-29 | 2016-04-08 | Eli Lilly And Company | N- (2-Arylethyl) benzylamines as 5-HT6 receptor antagonists |
| ES2327914T3 (en) | 2002-08-07 | 2009-11-05 | Novartis Ag | METHOD FOR FORECASTING THE SENSITIVITY OF RAVASTIGMINE TREATMENT BASED ON THE APOE GENOTYPE OF PACINTES WITH DEMENTIA. |
| TWI423802B (en) | 2007-05-22 | 2014-01-21 | Otsuka Pharma Co Ltd | A medicament for treating alzheimer's disease |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| RU2369600C1 (en) | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | SUBSTITUTED 4-SULPHONYL-PYRAZOLES AND 3-SULPHONYL-PYRAZOLO[1,5-a]PYRIMIDINES-ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, MEDICINAL AGENT AND METHOD OF OBTAINING THEM |
| NO2419104T3 (en) | 2009-04-13 | 2018-04-07 | ||
| WO2014165701A1 (en) * | 2013-04-03 | 2014-10-09 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| JO3459B1 (en) | 2012-09-09 | 2020-07-05 | H Lundbeck As | Pharmaceutical compositions for treating alzheimer's disease |
| CA2985366A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Gmbh | Methods of treating a neurodegenerative disease |
| RU2742173C2 (en) * | 2016-04-26 | 2021-02-02 | Х. Лундбекк А/C | Using the acetylcholinesterase and idalopirdine inhibitor to reduce the risk of falls in the patients with parkinson's disease |
| US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
-
2018
- 2018-05-22 DK DK18726791.9T patent/DK3630098T3/en active
- 2018-05-22 SG SG11201909895U patent/SG11201909895UA/en unknown
- 2018-05-22 MX MX2019013912A patent/MX2019013912A/en unknown
- 2018-05-22 SI SI201830258T patent/SI3630098T1/en unknown
- 2018-05-22 LT LTEP18726791.9T patent/LT3630098T/en unknown
- 2018-05-22 KR KR1020197032218A patent/KR102676011B1/en active IP Right Grant
- 2018-05-22 CA CA3063968A patent/CA3063968A1/en active Pending
- 2018-05-22 PT PT187267919T patent/PT3630098T/en unknown
- 2018-05-22 AU AU2018272883A patent/AU2018272883B2/en active Active
- 2018-05-22 ES ES18726791T patent/ES2869128T3/en active Active
- 2018-05-22 HU HUE18726791A patent/HUE053636T2/en unknown
- 2018-05-22 EP EP18726791.9A patent/EP3630098B1/en active Active
- 2018-05-22 CN CN201880033314.8A patent/CN111032038A/en active Pending
- 2018-05-22 RS RS20210449A patent/RS61704B1/en unknown
- 2018-05-22 BR BR112019001145-5A patent/BR112019001145A2/en active Search and Examination
- 2018-05-22 PL PL18726791T patent/PL3630098T3/en unknown
- 2018-05-22 JP JP2019564834A patent/JP7167065B2/en active Active
- 2018-05-22 WO PCT/EP2018/063402 patent/WO2018215478A1/en active Application Filing
- 2018-05-23 US US15/987,449 patent/US11464759B2/en active Active
-
2019
- 2019-11-13 ZA ZA2019/07525A patent/ZA201907525B/en unknown
-
2021
- 2021-04-14 CY CY20211100328T patent/CY1124282T1/en unknown
- 2021-04-22 HR HRP20210634TT patent/HRP20210634T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7167065B2 (en) | 2022-11-08 |
| ES2869128T3 (en) | 2021-10-25 |
| JP2020520964A (en) | 2020-07-16 |
| EP3630098A1 (en) | 2020-04-08 |
| DK3630098T3 (en) | 2021-04-26 |
| CN111032038A (en) | 2020-04-17 |
| AU2018272883A1 (en) | 2019-11-14 |
| CY1124282T1 (en) | 2022-07-22 |
| WO2018215478A1 (en) | 2018-11-29 |
| CA3063968A1 (en) | 2018-11-29 |
| BR112019001145A2 (en) | 2019-04-30 |
| ZA201907525B (en) | 2022-02-23 |
| RS61704B1 (en) | 2021-05-31 |
| SI3630098T1 (en) | 2021-07-30 |
| US20180353477A1 (en) | 2018-12-13 |
| KR102676011B1 (en) | 2024-06-17 |
| EP3630098B1 (en) | 2021-03-24 |
| MX2019013912A (en) | 2020-01-21 |
| RU2019135609A (en) | 2021-06-24 |
| AU2018272883B2 (en) | 2024-02-15 |
| LT3630098T (en) | 2021-05-25 |
| US11464759B2 (en) | 2022-10-11 |
| PL3630098T3 (en) | 2021-09-06 |
| RU2019135609A3 (en) | 2021-08-23 |
| HUE053636T2 (en) | 2021-07-28 |
| HRP20210634T1 (en) | 2021-05-28 |
| KR20200007795A (en) | 2020-01-22 |
| PT3630098T (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201804587QA (en) | Isoindole compounds |